Before revision:  Interestingly, a null model demonstrates that age and women-specific risks from increased polypharmacy far exceed expectations in those populations.
After revision:  Interestingly, a null model demonstrates that age and women-specific risks from increased polypharmacy fail by far to explain the observed risks of DDI in those populations.